No Data
No Data
China Grants Clinical Trial Approval for Anti-Cancer Injections
China's medical products administrator approved Jiangsu Hengrui Pharmaceutical's clinical trials for the SHR-9839, SHR-A1921, and SHR-A2009 injectables, according to a Sunday filing by the Shanghai St
Hengrui Pharmaceutical (600276.SH): The subsidiary SHR-A1921 for injectable drugs will be included in the list of breakthrough treatment varieties announced
Gelonghui May 26 丨 Hengrui Pharmaceutical (600276.SH) announced that the injectable SHR-A1921 of the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. was proposed to be included in the publication list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration (referred to as the “Drug Review Center”). The publicity period is 7 days. SHR-A1921 for injection is an antibody-drug conjugate (ADC) targeting TROP-2 tumor-related antigen. By binding to the target antigen on the surface of tumor cells, the drug releases small molecules of toxins to kill tumor cells after being endocytosed into the cell. TROP-2 is a broad expression
Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs
China's medical products administrator granted Jiangsu Hengrui Pharmaceuticals (SHA:600276) a drug registration certificate for its fluzoparib capsules for platinum-sensitive recurrent ovarian cancer
Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Jiangsu Hengrui Medicine's (SHSE:600276) stock increased significantly by 5.1% over the past month. As most would know, fundamentals are what usually guide m
Hengrui Pharmaceutical (600276.SH): Fluzopalil capsules obtained drug registration certificate
Glonghui, May 21丨Hengrui Pharmaceutical (600276.SH) announced that it has received approval from the China Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Registration Certificate” for fluzopalil capsules, and approved the launch of a Class 1 new drug developed by the company and a new indication of the PARP inhibitor fluzopalil capsules. This is the 3rd indication that fluzopalil has been approved for marketing.
Hengrui Pharma Misses US FDA Approval for Cancer Injection
The US Food and Drug Administration issued Jiangsu Hengrui Pharmaceuticals' (SHA:600267) a complete response letter for its Camrelizumab injectable for certain cancers, according to a Friday filing wi
No Data